Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
- Data from Phase 3 innovaTV 301 trial to be reviewed -
Pfizer Receives Positive CHMP Opinion for its 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) Candidate for Infants and Children
- 20vPnC offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine (PCV), helping to protect infants and children against all 20 serotypes contained in the vaccine
- Together, the 20 serotypes included in 20vPnC are responsible for the majority of currently circulating pneumococcal disease in the EU and globally 1,2,3,4,5,6,7,8
- The vaccine candidate builds on PREVENAR 13® and includes seven additional serotypes that are global causes of invasive pneumococcal disease (IPD) and are associated with high case-fa
Pfizer Presents New Cancer Research at ASCO GU Cancers Symposium
This week, from January 25-27th, Pfizer will join the genitourinary oncology community at the 20th annual meeting of the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium.
Pfizer Awards $2M to Nonprofit Organizations Addressing Systemic Health Inequities
Equity is a core value at Pfizer, and we have a longstanding commitment to helping resolve deeply ingrained systemic health inequities.
CEO Albert Bourla Kicks Off Pfizer’s 175th Anniversary Celebration
For 175 years, Pfizer has been at the forefront of medical and pharmaceutical breakthroughs that have not only changed patient lives but have impacted the world.
Hospira, Inc. Issues A Voluntary Nationwide Recall For 4.2% Sodium Bicarbonate Injection, USP ABBOJECT® Syringe; 8.4% Sodium Bicarbonate Injection, USP Lifeshield® ABBOJECT® Syringe; and Atropine Sulfate Injection, USP Lifeshield® ABBOJECT® Syringe
Recall due to the Potential For Presence of Glass Particulate Matter
FOR IMMEDIATE RELEASE - December 21, 2023 - NEW YORK, NY.
Hospira, Inc. Issues A Voluntary Nationwide Recall For One Lot of Bleomycin for Injection, USP 15 Units Single Dose ONCO-TAIN™ Glass Fliptop Vial Due To The Potential For Presence of Glass Particulate Matter
FOR IMMEDIATE RELEASE - December 21, 2023 - NEW YORK, NY.
Hospira, Inc., a Pfizer company, is voluntarily recalling one lot of Bleomycin for Injection, USP 15 units Single Dose ONCO-TAIN™ Glass Fliptop Vial, lot BL12206A, to the user level. The recall was initiated due to a confirmed customer report for the presence of glass particulate within a single vial.
Pfizer Accelerates Climate Action through Pan-European Virtual Power Purchase Power Agreements
The impact of climate change on human health is unequivocal. Guided by our company purpose, “Breakthroughs that change patients’ lives”, Pfizer remains committed to reducing our company’s greenhouse gas (GHG) emissions.
Pfizer Launches VaxAssist, to Help Individual’s Assess Respiratory Vaccine Eligibility
As more respiratory vaccinations have become available in recent years, the Centers for Disease Control and Prevention (CDC) continues to provide annual guidelines for common respiratory illnesses—COVID-19, pneumococcal pneumonia, influenza (the flu), and respiratory syncytial virus (RSV)—to help ensure eligible populations are seeking vaccinations, especially during respiratory illness season.
Pfizer Receives Positive CHMP Opinion for Ulcerative Colitis Treatment
NEW YORK, December 15, 2023 – Pfizer Inc. (NYSE: PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.